T2*加权MRI作为无对比剂增强方法评估前列腺癌热疗中局灶激光消融范围
研究纳入14例活检证实的低至中危局限性前列腺癌患者,在1.5T MRI引导下接受局灶激光消融热疗,比较T2*加权MRI与增强T1加权MRI评估消融范围。结果显示T2*加权图像上消融区CBR与增强减影T1加权图像无差异,长TE T2*加权ROI大小与增强减影T1加权强相关且差异在15%以内,提示T2*加权MRI可作为术中监测FLA的潜在方法。
要点
- 长TE T2*加权MRI可显示局灶激光消融区,效果与增强T1加权MRI相当。
- T2*加权(TE=63ms)ROI大小与增强减影T1加权强相关(r=0.64,p=0.013),差异在15%以内。
- T2*加权MRI可能用于术中重复监测消融区,避免对比剂加热的潜在毒性。
关键影像表现/征象
- T2*加权图像(TE=32、63ms)上消融ROI的CBR与减影增强T1加权图像无差异(p=0.33、0.25)。
- Bland-Altman图显示T2*加权(TE=32、63ms)与减影增强T1加权图像在ROI大小和CBR上一致性良好。
- T2*加权(TE=63ms)ROI大小与减影增强T1加权强相关(r=0.64,p=0.013),差异在15%以内。
临床应用与阅片要点
- 长TE T2*加权MRI可术中识别前列腺癌局灶激光消融区范围,与增强T1加权MRI结果相当。
- T2*加权MRI可能作为术中重复监测热消融区的无对比剂方法,避免对比剂加热的潜在毒性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate utility of T2*-weighted (T2*W) MRI as a tool for intra-operative identification of ablation zone extent during focal laser ablation (FLA) of prostate cancer (PCa), as compared to the current standard of contrast-enhanced T1-weighted (T1W) MRI.
METHODS: Fourteen patients with biopsy-confirmed low- to intermediate-risk localized PCa received MRI-guided (1.5 T) FLA thermotherapy. Following FLA, axial multiple-TE T2*W images, diffusion-weighted images (DWI), and T2-weighted (T2W) images were acquired. Pre- and post-contrast T1W images were also acquired to assess ablation zone (n = 14) extent, as reference standard. Apparent diffusion coefficient (ADC) maps and subtracted contrast-enhanced T1W (sceT1W) images were calculated. Ablation zone regions of interest (ROIs) were outlined manually on all ablated slices. The contrast-to-noise ratio (CBR) of the ablation site ROI relative to the untreated contralateral prostate tissue was calculated on T2*W images and ADC maps and compared to that in sceT1W images.
RESULTS: CBRs in ablation ROIs on T2*W images (TE = 32, 63 ms) did not differ (p = 0.33, 0.25) from those in sceT1W images. Bland-Altman plots of ROI size and CBR in ablation sites showed good agreement between T2*W (TE = 32, 63 ms) and sceT1W images, with ROI sizes on T2*W (TE = 63 ms) strongly correlated (r = 0.64, p = 0.013) and within 15% of those in sceT1W images.
CONCLUSIONS: In detected ablation zone ROI size and CBR, non-contrast-enhanced T2*W MRI is comparable to contrast-enhanced T1W MRI, presenting as a potential method for intra-procedural monitoring of FLA for PCa.
KEY POINTS: • T2*-weighted MR images with long TE visualize post-procedure focal laser ablation zone comparably to the contrast-enhanced T1-weighted MRI. • T2*-weighted MRI could be used as a plausible method for repeated intra-operative monitoring of thermal ablation zone in prostate cancer, avoiding potential toxicity due to heating of contrast agent.
引用
- Sun C, Wang S, Chatterjee A, et al. T2*-weighted MRI as a non-contrast-enhanced method for assessment of focal laser ablation zone extent in prostate cancer thermotherapy. Eur Radiol. 2020. PMID: 32785769. doi:10.1007/s00330-020-07127-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。